Mirati Therapeutics Inc.
Clinical trials sponsored by Mirati Therapeutics Inc., explained in plain language.
Oncology biotech focused on targeted cancer therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a cancer drug be tailored for japanese patients? a new trial seeks answers Results expected Sep 2026 (estimated)
- New drug cocktail targets Hard-to-Treat lung cancer mutation Results expected Sep 2026 (estimated)
- Lung cancer drug adagrasib: which dose works best? Results expected Oct 2026 (estimated)
-
New hope for KRAS lung cancer: targeted combo enters phase 3 trial
Disease control Recruiting nowThis phase 3 trial tests whether adding the targeted drug adagrasib to standard immunotherapy and chemotherapy can help people with a specific genetic subtype of advanced lung cancer (KRAS G12C mutation) live longer without their cancer growing. About 630 adults who have not had …
Phase 3 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for hard-to-treat lung cancer: targeted drug plus immunotherapy tested
Disease control Recruiting nowThis study tests a drug called adagrasib, alone or with pembrolizumab (an immunotherapy), in people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if the combination shrinks tumors and helps people live longer without t…
Phase 2/3 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Cancer drug adagrasib offers continued hope in rollover trial
Disease control Recruiting nowThis study provides ongoing treatment with the cancer drug adagrasib (BMS-986503) to patients with advanced solid tumors who have already seen benefit in earlier studies. About 170 adults with non-small cell lung cancer, colorectal cancer, or other solid tumors can join if they a…
Phase 2 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Can a cancer drug be tailored for japanese patients? a new trial seeks answers
Knowledge-focused Recruiting nowThis early-stage study is testing how a single dose of the experimental cancer drug adagrasib is processed by the body in 10 healthy adults of Japanese descent. Researchers will measure drug levels in the blood and monitor for any side effects. The goal is to gather safety and ph…
Phase 1 • Sponsor: Mirati Therapeutics Inc. • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC